Related Experiment Video
Updated: Feb 6, 2026

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
Published on: October 9, 2015
Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells
Matteo Turetta1, Michela Bulfoni2, Giulia Brisotto3,4,5
1Department of Medicine, University of Udine, P.le Kolbe 4, 33100 Udine, Italy. matteo.turetta@uniud.it.
Abstract:
Molecular characterization is currently a key step in NSCLC therapy selection. Circulating tumor cells (CTC) are excellent candidates for downstream analysis, but technology is still lagging behind. In this work, we show that the mutational status of NSCLC can be assessed on hypermetabolic CTC, detected by their increased glucose uptake. We validated the method in 30 Stage IV NSCLC patients: peripheral blood samples were incubated with a fluorescent glucose analog (2-NBDG) and analyzed by flow cytometry. Cells with the highest glucose uptake were sorted out. EGFR and KRAS mutations were detected by ddPCR. In sorted cells, mutated DNA was found in 85% of patients, finding an exact match with primary tumor in 70% of cases. Interestingly, in two patients multiple KRAS mutations were detected. Two patients displayed different mutations with respect to the primary tumor, and in two out of the four patients with a wild type primary tumor, new mutations were highlighted: EGFR p.746_750del and KRAS p.G12V. Hypermetabolic CTC can be enriched without the need of dedicated equipment and their mutational status can successfully be assessed by ddPCR. Finally, the finding of new mutations supports the possibility of probing tumor heterogeneity.
Insights
This study identifies hypermetabolic circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients. These cells can be analyzed for mutations, aiding in therapy selection and revealing tumor heterogeneity.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Molecular characterization is crucial for non-small cell lung cancer (NSCLC) therapy selection.
- Circulating tumor cells (CTCs) offer potential for molecular analysis, but current technologies face limitations.
Purpose of the Study:
- To assess the mutational status of NSCLC using hypermetabolic CTCs detected by their glucose uptake.
- To validate a method for enriching and analyzing CTCs for EGFR and KRAS mutations.
Main Methods:
- Peripheral blood samples from 30 Stage IV NSCLC patients were incubated with a fluorescent glucose analog (2-NBDG).
- Hypermetabolic CTCs were sorted using flow cytometry based on high glucose uptake.
- EGFR and KRAS mutations in sorted CTCs were detected using droplet digital PCR (ddPCR).
Main Results:
- Mutated DNA was detected in 85% of sorted CTCs, with 70% matching the primary tumor's mutations.
- New mutations (EGFR p.746_750del, KRAS p.G12V) were identified in patients with wild-type primary tumors.
- Multiple KRAS mutations were found in two patients, and discordant mutations were observed in two others.
Conclusions:
- Hypermetabolic CTCs can be enriched without specialized equipment and their mutational status successfully assessed by ddPCR.
- This method facilitates non-small cell lung cancer (NSCLC) molecular profiling and therapy selection.
- The detection of novel mutations in CTCs highlights their utility in probing tumor heterogeneity.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Coronary Circulation
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
Fetal Circulation
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...

